©2024 Stanford Medicine
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Not Recruiting
Trial ID: NCT00892931
Purpose
The purpose of this study is to determine the safety and effectiveness of Azixa in patients
with recurrent glioblastoma multiforme
Official Title
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
Stanford Investigator(s)
Lawrence Recht, MD
Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
- Have histologically proven malignant Glioblastoma Multiforme in first or second
relapse
- Have failed prior Fractionated External Beam Cranial Irradiation or IMRT
- Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed
prior Avastin therapy
- Have a Karnofsky performance status of ≥ 60
- Have adequate bone marrow function, liver function, and renal function before starting
therapy
Exclusion Criteria:
- Have had more than two relapses
- Have had radiosurgery
- Have a cardiac ejection fraction < 50% by MUGA or ECHO
- Have Troponin-I elevated above the normal range
- Have an increasing steroid requirement
- Have MRI evidence at baseline of enlarging or clinically significant intratumor
hemorrhage
- Have active stroke and/or transient ischemic attack not optimally managed
- Have active cardiovascular disease (e.g. sub-optimally managed angina, impending
myocardial infarction, or uncontrolled hypertension)
- Be pregnant or breast feeding
- Have had prior hypersensitivity reaction to Cremophor EL
- Be HIV positive
Intervention(s):
drug: Azixa
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061